tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

BeOne Medicines price target raised to $360 from $334 at TD Cowen

TD Cowen raised the firm’s price target on BeOne Medicines (ONC) to $360 from $334 and keeps a Buy rating on the shares. The firm notes Q2 Brukinsa beat with $950M. GAAP profitability from beats for tisle and Amgen (AMGN) products plus tight OpEx control.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1